RxDoctor Payments Data

Eric Ritter, MD

Hospitalist · Baltimore, MDNPI 1659557593

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $91,525 of the $93,781 with a category attached, or 97.6%. AbbVie accounts for 99.5% of it on its own, with 5 other manufacturers making up the rest. Among hospitalist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$93,781in general payments, 2019–2025

Across 191 payments — averaging $491.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$93K
  • Medtronic$155
  • E.r. Squibb & Sons, L.L.C.$122
  • Indivior Inc.$110
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$68
  • Orexo US, Inc.$23

What the payments were for

  • Speaking & faculty fees$91,52598%
  • Travel & lodging$1550%
  • Food & beverage$2,0542%
  • Education$470%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$93,781 in reported general payments places this provider in the 95th percentile of 414 hospitalist providers in Maryland.

See all hospitalist providers in Maryland

Medicare billing

Part B allowed, 2024
$28,297
Medicare patients
14
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuboxoneBuprenorphine Hcl/Naloxone Hcl58$32,177
VraylarCariprazine Hcl15$21,367
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl92$19,202
EliquisApixaban19$9,753
Quetiapine Fumarate ErQuetiapine Fumarate39$2,129
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,907
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,477
Albuterol Sulfate HfaAlbuterol Sulfate52$1,410
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,003
Diclofenac Sodium26$901
Gabapentin94$720
Aripiprazole28$558
Famotidine30$308
Omeprazole31$268
Lisinopril70$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$110$32,17758 claims
AbbVieVraylar$93,302$21,36715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 414 hospitalist providers in Maryland.

Other hospitalist in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →